TARS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
194.6M
+11.9%
173.9M
+7.3%
162.1M
+6.8%
151.7M
+27.8%
118.7M
Cost of Revenue
13.9M
+14.7%
12.1M
+28.9%
9.4M
-14.0%
10.9M
+31.5%
8.3M
Gross Profit
180.7M
+11.7%
161.8M
+6.0%
152.7M
+8.5%
140.7M
+27.5%
110.4M
Operating Expenses
842.8M
+363.8%
181.7M
+14.4%
158.8M
+6.8%
148.7M
+19.1%
124.9M
R&D
676.4M
+2081.1%
31.0M
+38.7%
22.4M
+23.9%
18.0M
+10.8%
16.3M
SG&A
168.0M
+11.5%
150.7M
+10.5%
136.4M
+4.4%
130.7M
+20.3%
108.6M
Operating Income
-662094000
-3225.8%
-19908000
-225.2%
-6122000
+23.2%
-7976000
+45.1%
-14529000
EBITDA
-661067000
-3560.6%
-18059000
-176.4%
-6534000
+49.8%
-13015000
+7.5%
-14069000
Net Income
-668334000
-3502.7%
-18551000
-166.3%
-6967000
+16.8%
-8373000
+33.5%
-12585000
EPS (Basic)
$-14.40
-3248.8%
$-0.43
-168.8%
$-0.16
+15.8%
$-0.19
+36.7%
$-0.30
EPS (Diluted)
$-14.40
-3248.8%
$-0.43
-168.8%
$-0.16
+15.8%
$-0.19
+36.7%
$-0.30
Shares (Diluted)
46.4M
+7.0%
43.4M
+1.0%
43.0M
+0.3%
42.8M
+0.5%
42.6M
Tarsus Pharmaceuticals (TARS) — Financials